A randomised trial of epirubicin versus mitomycin C at the time of first recurrence in superficial bladder cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN77353795

Enrollment

800

Registered

2001-02-28

Start date

1994-04-22

Completion date

Unknown

Last updated

2018-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer Cancer Bladder cancer

Interventions

First randomisation is between irrigation of the bladder with glycine/saline and no irrigation. The second randomisation is between Epodye and mitomycin C.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly-diagnosed superficial carcinoma of bladder suitable for complete endoscopic resection, limited to the bladder 2. World Health Organisation (WHO) status zero to two 3. Expected survival at least three years 4. No history of other malignant tumours, except non-melanomatous skin tumours, or carcinoma in-situ (CIN) 5. No untreated urinary tract infection (UTI)

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Local recurrence, time to progression, metastases, morbidity	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026